

# Product information



Information about other products is available at: [www.IBL-America.com](http://www.IBL-America.com)

## ImmunoGuide®

### Instructions for Use

## Adalimumab ELISA

Enzyme immunoassay for the determination  
of free Adalimumab in serum and plasma

REF: TM09008



12X8



2-8°C

**For Research Use Only - Not for Use in Diagnostic Procedures**

Manufactured for  
**Immuno-Biological Laboratories Inc. (IBL-America)**  
8201 Central Avenue, NE, Suite P  
Minneapolis, MN 55432  
Tel: 763-780-2955 Toll Free: 1-888-523-1246  
[www.IBL-America.com](http://www.IBL-America.com)

<b><u>Contents</u></b>	<b><u>Page</u></b>
1. Intended Use	2
2. Summary and Explanation	2
3. Principle of the Test	2
4. Warnings and Precautions	2
5. Storage and Stability of the Kit	3
6. Specimen Collection, Handling and Storage	3
7. Contents of the Kit	4
8. Materials Required but not Supplied	4
9. Procedure Notes	5
10. Pre-Test Setup Instructions	5
10.1. Preparation of Components	5
10.2. Dilution of Standards and Samples	6
11. Test Procedure	6
11.1. General Remarks	6
11.2. Assay Procedure	7
11.3. Quality Control	8
11.4. Calculation of Results	8
12. Assay characteristics	9
12.1. Specificity	9
12.2. Sensitivity	9
12.3. Precision	10
12.4. Recovery	10
13. Automation	10
14. References	10

## 1. INTENDED USE

Enzyme immunoassay for the determination of free Adalimumab in serum and plasma.

## 2. SUMMARY AND EXPLANATION

The drug Adalimumab (trade name Humira®) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor alpha (TNF- $\alpha$ ). Adalimumab was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1: $\kappa$  constant regions. Adalimumab is produced by recombinant DNA technology in a mammalian cell expression system and it consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons. Adalimumab binds specifically to (TNF- $\alpha$ ) and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.

Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Adalimumab in order to potentially avoid some side effects with a reliable method might be beneficial.

## 3. PRINCIPLE OF THE TEST

This ELISA assay is based on sandwich type ELISA. Diluted standards and samples (serum or plasma) are incubated in the microtiter plate coated with recombinant human TNF- $\alpha$  (rh TNF- $\alpha$ ). After incubation, the wells are washed. A horseradish peroxidase (HRP) conjugated anti-human IgG monoclonal antibody is added and binds to the Fc part of Adalimumab pre-captured by the rhTNF- $\alpha$  on the surface of the wells. Following incubation, the wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. The color developed is proportional to the amount of free Adalimumab in the sample or standard. Results of samples can be determined by using the standard curve.

## 4. WARNINGS AND PRECAUTIONS

1. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood. For further information (clinical background, test performance, automation protocols, alternative applications, literature, etc.) please refer to the local distributor.
2. In case of severe damage of the kit package, please contact *IBL-America* or your supplier in writing, latest one week after receiving the kit. Do not use damaged components in test runs, but keep safe for complaint related issues.
3. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
4. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
5. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details.

6. Chemicals and prepared or used reagents have to be treated as hazardous waste according the national biohazard safety guidelines or regulations.

7. Avoid contact with Stop solution. It may cause skin irritations and burns.

8. If any component of this kit contains human serum or plasma it is indicated and if so, it has been tested and were found to be negative for HIV I/II, HBsAg and HCV. However, the presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.

9. Some reagents contain sodium azide ( $\text{NaN}_3$ ) as preservatives. In case of contact with eyes or skin, flush immediately with water.  $\text{NaN}_3$  may react with lead and copper plumbing to form explosive metal azides. When disposing reagents, flush with large volume of water to avoid azide build-up

## 5. STORAGE AND STABILITY OF THE KIT

The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The storage and stability of specimen and prepared reagents is stated in the corresponding chapters. The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2–8°C.

## 6. SPECIMEN COLLECTION, HANDLING AND STORAGE

### Serum, Plasma (EDTA, Heparin)

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

Storage:	2-8°C	$\leq -20^\circ\text{C}$ (Aliquots)	Keep away from heat or direct sun light Avoid repeated freeze-thaw cycles
Stability:	3 d	6 mon	

## 7. CONTENTS OF THE KIT

QUANTITY	COMPONENT
1 x 12 x 8	<b>Microtiter ELISA Plate</b> Break apart strips coated with recombinant human TNF- $\alpha$ (rhTNF- $\alpha$ )
5 x 0.5 mL	<b>Adalimumab Standards A-E, Concentrate (10X)</b> 2000; 600; 200; 60; and 0 ng/mL Used for construction of the standard curve. Contains Adalimumab, proteins, stabilizer and <15 mM NaN <sub>3</sub> .
1 x 12 mL	<b>Assay Buffer</b> Blue colored. Ready to use. Contains proteins and <15 mM NaN <sub>3</sub> .
1 x 60 mL	<b>Dilution Buffer, Concentrate (5X)</b> Contains orange dye, proteins and <15 mM NaN <sub>3</sub> .
1 x 12 mL	<b>Enzyme Conjugate</b> Red colored. Ready to use. Contains horseradish peroxidase(HRP)-conjugated anti-human IgG mouse monoclonal antibody, Proclin <sup>®</sup> and stabilizers.
1 x 12 mL	<b>TMB Substrate Solution</b> Ready to use. Contains 3,3',5,5'-Tetramethylbenzidine (TMB).
1 x 12 mL	<b>Stop Solution</b> Ready to use. 1 N Hydrochloric acid (HCl).
1 x 50 mL	<b>Wash Buffer, Concentrate (20x)</b> Contains buffer, Tween <sup>®</sup> 20 and Kathon <sup>™</sup> .
2 x 1	<b>Adhesive Seal</b> For sealing microtiter plate during incubation.

## 8. MATERIALS REQUIRED BUT NOT SUPPLIED

1. Micropipettes (< 3% CV) and tips to deliver 5-1000  $\mu$ L.
2. Bidistilled or deionised water and calibrated glasswares (e.g. flasks or cylinders).
3. Wash bottle, automated or semi-automated microtiter plate washing system.
4. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength at 600-650 nm is optional).
5. Absorbent paper towels, standard laboratory glass or plastic vials, and a timer.

## 9. PROCEDURE NOTES

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pre-treatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared readily at the appropriate time. Allow all reagents and specimens to reach room temperature (20-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each reagent, standard or specimen. Do not interchange the caps of vials. Always cap not used vials. Do not reuse wells or reagents.
4. Use a pipetting scheme to verify an appropriate plate layout.
5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.
6. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
7. Humidity affects the coated wells. Do not open the pouch until it reaches room temperature. Unused wells should be returned immediately to the resealed pouch including the desiccant.

## 10. PRE-TEST SETUP INSTRUCTIONS

### 10.1. Preparation of Components\*

Dilute/dissolve	Component		Diluent	Relation	Remarks	Storage	Stability
10 mL	Wash Buffer	up to 200 mL	Distilled Water	1:20	Warm up at 37°C to dissolve crystals. Mix vigorously.	2-8 °C	4 w
10 mL	Dilution Buffer	up to 50 mL	Distilled Water	1:5		2-8 °C	4 w


\* Prepare Wash and Dilution Buffers before starting the assay procedure.

## 10.2. Dilution of Standards and Samples

The dilutions depicted below are examples of how to obtain final dilutions for standards and samples. Standards and samples should be properly diluted as homogenous mixture before starting the assay procedure. It is recommended mixing the standards and samples well to homogenous solution at each dilution step. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

1. 10  $\mu\text{L}$  of standard added to 90  $\mu\text{L}$  of 1X dilution buffer, giving the total volume of 100  $\mu\text{L}$  and a dilution of 1:10.
2. 10  $\mu\text{L}$  of sample added to 490  $\mu\text{L}$  of 1X dilution buffer, giving the total volume of 500  $\mu\text{L}$  and a dilution of 1:50.
3. Samples with a drug concentration above the measuring range should be rated as ">highest standard". The result should not be extrapolated. The sample in question should be further diluted with 1X Dilution Buffer and then retested.

### Standard/Sample Dilution



## 11. TEST PROCEDURE

### 11.1. GENERAL REMARKS

- 11.1.1. Before performing the assay, samples and assay kit should be brought to room temperature (about 30 minutes beforehand) and ensure the homogeneity of the solution.
- 11.1.2. All Standards should be run with each series of unknown samples.
- 11.1.3. Standards should be subject to the same manipulations and incubation times as the samples being tested.

11.1.4. All steps of the test should be completed without interruption. 11.1.5. Use new disposable plastic pipette tips for each reagent, standard or specimen in order to avoid cross contamination.

11.1.6. The total pipetting time needed for dispensing all samples into the wells should not exceed 5 minutes. If this is difficult to achieve the samples should be pre-dispensed in a separate neutral polypropylene microplate and then transferred into the reaction ELISA plate by a multi channel pipette. Such neutral plates are available from the kit manufacturer upon request.

## 11.2. ASSAY PROCEDURE

1.	Pipette <b>100 µL</b> of <b>Assay Buffer</b> into each of the wells to be used.
2.	Pipette <b>75 µL</b> of each <b>1:10 Diluted Standard, and 1:50 Diluted Samples</b> into the respective wells of the microtiter plate. Bubble formation during the pipetting of standards and samples must be avoided. <u>Wells</u> A1: Standard A B1: Standard B C1: Standard C D1: Standard D E1: Standard E F1 and so on: Samples (Serum/Plasma)
3.	Cover the plate with adhesive seal. Shake plate carefully by tapping several times. <b>Incubate the plate on a bench top for 60 min at room temperature (RT, 20-25°C).</b>
4.	Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate <b>3 X 300 µL</b> of <b>Diluted Wash Buffer</b> per well. Remove excess solution by tapping the inverted plate on a paper towel.
5.	Pipette <b>100 µL</b> of <b>Enzyme Conjugate</b> (HRP-anti human IgG mAb) into each well.
6.	Cover plate with adhesive seal. Shake plate carefully by tapping several times. <b>Incubate the plate on a bench top for 30 min</b> at RT.
7.	Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate <b>3 X 300 µL</b> of <b>Diluted Wash Buffer</b> per well. Remove excess solution by tapping the inverted plate on a paper towel.
8.	Pipette <b>100 µL</b> of Ready-to-Use <b>TMB Substrate Solution</b> into each well.
9.	<b>Incubate 15 min</b> at RT. Avoid exposure to direct sunlight.
10.	Stop the substrate reaction by adding <b>100 µL</b> of <b>Stop Solution</b> into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow.
11.	Measure optical density (OD) with a photometer at <b>450 nm</b> (Reference at OD620 nm is optional) within <b>15 min</b> after pipetting the Stop Solution.



### 11. 3. QUALITY CONTROL

The test results are only valid if the test has been performed following the instructions. Moreover, the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. A separate 2-level control is available upon request (cat.-noTM09008-QC). All standards/controls must be found within the acceptable ranges. If the criteria are not met, the run is not valid and should be repeated. In case of any deviation, the following technical issues should be reviewed: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.


### 11. 4. CALCULATION OF RESULTS

A standard curve should be calculated using the standard concentration (X-axis) versus the OD450 (or OD450/620) values (Y-axis). This can be done manually using graph paper or with a computer program. Concerning the data regression by computer, it is recommended to primarily use the "4 Parameter Logistic (4PL)" or alternatively the "point-to-point calculation". In case of manual plot there are 2 options: Semilog graph (see Fig. A) or linear graph (see Fig. B). Semilog graph paper is available at <http://www.papersnake.com/logarithmic/semilogarithmic/>. The concentration of the samples can be read from this standard curve as follows. Using the absorbance value for each sample, determine the corresponding concentration of the drug from the standard curve. This value always has to be multiplied by the individual dilution factor (usually 50). If any diluted sample is reading greater than the highest standard, it should be further diluted appropriately with 1X Dilution Buffer and retested. Also, this second dilution has to be used for calculation of the final result. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

### Typical Calibration Curve

(All steps were performed at 23°C. Just an example. Do not use it for calculation!)

1:10 Diluted Standard	A	B	C	D	E
Concentration (ng/mL)	200	60	20	6	0
Mean OD <sub>450/620 nm</sub>	2.805	0.981	0.384	0.126	0.048



## 12. ASSAY CHARACTERISTICS

### 12.1. SPECIFICITY

There is no cross reaction with any other proteins present in naïve serum. Because the solid phase is coated with rhTNF- $\alpha$ , other therapeutic anti-TNF antibodies cause full cross reaction. However, a quantification of other therapeutic antibodies is possible only by using the drug-specific standards, which are available as separate kits from *ImmunoGuide*.

### 12.2. SENSITIVITY

The lowest detectable level that can be clearly distinguished from the zero standard is 5 ng/mL (zero standard +2SD read from the curve) under the above-described conditions.

### 12.3. PRECISION

**Intra-assay CV:** <10%.

**Inter-assay CV:** <10%.

### 12.4. RECOVERY

Recovery rate was found to be >95% with native serum and plasma samples when spiked with exogenous Adalimumab.

### 13. AUTOMATION

The *ImmunoGuide* Adalimumab ELISA is suitable also for being used by an automated ELISA processor.

### 14. REFERENCES

1. Romero G, Ochoteco O, Sanz DJ, Estrela-Lopis I, Donath E, Moya SE. Poly(lactide-co-glycolide) nanoparticles, layer by layer engineered for the sustainable delivery of antiTNF- $\alpha$ . *Macromol Biosci*. 2013 Jul;13(7):903-12.
2. Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. *J Dermatol*. 2013;40(1):39-42.
3. Gutiérrez A, Scharl M, Sempere L, Holler E, Zapater P, Almenta I, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R. Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. *Gut*. 2014;63(2):272-80.
4. Oh K, Ito S, Unno M, Kobayashi D, Azuma C, Abe A, Otani H, Ishikawa H, Nakazono K, Narita I, Murasawa A. The rate of decrease in the disease activity of rheumatoid arthritis during treatment with adalimumab depends on the dose of methotrexate. *Intern Med*. 2015;54(9):1035-41.
5. Chen DY, Chen YM, Hsieh TY, Hung WT, Hsieh CW, Chen HH, Tang KT, Lan JL. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up. *Rheumatology (Oxford)*. 2015 Aug 31. pii: kev298.
6. Brandse JF, Vos LM, Jansen J, Schakel T, Ponsioen CI, van den Brink GR, D'Haens GR, Löwenberg M. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment. *J Crohns Colitis*. 2015;9(11):973-81.
7. Eng GP, Bendtzen K, Bliddal H, Stoltenberg M, Szkudlarek M, Fana V, Lindegaard HM, Omerovic E, Højgaard P, Jensen EK, Bouchelouche PN. Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study. *Arthritis*. 2015;2015:784825. doi: 10.1155/2015/784825.
8. Bodini G, Savarino V, Peyrin-Biroulet L, de Cassan C, Dulbecco P, Baldissarro I, Fazio V, Giambruno E, Savarino E. Low serum trough levels are associated with

post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. *Dig Liver Dis.* 2014;46(11):1043-6.

9. Tanida S, Mizoshita T, Nishie H, Ozeki K, Katano T, Kubota E, Kataoka H, Kamiya T, Joh T. Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis. *J Clin Med Res.* 2015;7(11):884-9.

10. Sohn IW, Kim ST, Kim B, Lee HJ, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Efficacy of Adalimumab in Korean Patients with Crohn's Disease. *Gut Liver.* 2015 Oct 19. doi: 10.5009/gnl15165.

11. Fox JD, Baquerizo-Nole KL, Keegan BR, Macquhae F, Escandon J, Espinosa A, Perez C, Romanelli P, Kirsner RS. Adalimumab treatment leads to reduction of tissue tumor necrosis factor-alpha correlated with venous leg ulcer improvement: a pilot study. *Int Wound J.* 2015 Sep 24. doi: 10.1111/iwj.12497.

12. Bálint A, Farkas K, Palatka K, Lakner L, Miheller P, Rác Z, Hegede G, Vincze Á, Horváth G, Szabó A, Nagy F, Szepes Z, Gábor Z, Zsigmond F, Zsóri Á, Juhász M, Csontos Á, Szűcs M, Bor R, Milassin Á, Rutka M, Molnár T. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice. *J Crohns Colitis.* 2015 Sep 20. pii: jjv169.

13. Migliore A, Bizzi E, Egan CG, Bernardi M, Petrella L. Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. *Ther Clin Risk Manag.* 2015;11:1325-35.

14. Sagami S, Ueno Y, Tanaka S, Nagai K, Hayashi R, Chayama K. Successful Use of Adalimumab for Treating Pyoderma Gangrenosum with Ulcerative Colitis under Corticosteroid-tapering Conditions. *Intern Med.* 2015;54(17):2167-72.

15. Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, Bardales R, Elashoff D, Vangala S, Furst DE. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. *BioDrugs.* 2015 Aug;29(4):241-58.

16. Otsuka A, Morita M, Yamada H. Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab. *J Orthop Sci.* 2015 Aug 6.

17. Real-Fernández F, Cimaz R, Rossi G, Simonini G, Giani T, Pagnini I, Papini AM, Rovero P. Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization. *Anal Bioanal Chem.* 2015;407(24):7477-85.

18. Arstikyte I, Kapleryte G, Butrimiene I, Venalis A. Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF  $\alpha$  Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients. *Biomed Res Int.* 2015;2015:604872. doi: 10.1155/2015/604872. Epub 2015 Apr 27.

19. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. *Ann Rheum Dis.* 2013;72(12):1947-55.

20. Deehan M, Garcês S, Kramer D, Baker MP, Rat D, Roettger Y, Kromminga A. Managing unwanted immunogenicity of biologicals. *Autoimmun Rev.* 2015;14(7):569-74.